

LIST OF FIGURES

Figure No.	Description	Page No.
1-1	Receptors involved in Emesis	2
2-1	Types of Sustained Release Injectable Formulations	32
3-1A	Wajima profiles A: Amisulpride	72
3-1B	Wajima profiles B: Granisetron	73
3-2A	Dedrick plots A: Amisulpride	74
3-2B	Dedrick plots B: Granisetron	74
3-3A	PBPK model of Amisulpride A) IV Amisulpride 10 mg	77
3-3B	PBPK model of Amisulpride B) Single dose oral Amisulpride 50 mg	77
3-3C	PBPK model of Amisulpride C) Multiple dose oral Amisulpride 10 mg	77
3-4A	PBPK model of Granisetron A) IV Granisetron 3 mg	80
3-4B	PBPK model of Granisetron B) IV Granisetron 100 mcg/kg	80
3-4C	PBPK model of Granisetron C) Single dose oral Granisetron 1 mg	80
3-4D	PBPK model of Granisetron D) Multiple dose oral Granisetron 1 mg	80
3-4E	PBPK model of Granisetron E) Multiple dose oral Granisetron 2 mg	80
3-4F	PBPK model of Granisetron F) Subcutaneous (SC) Injection Granisetron 3 mg	80
3-4G	PBPK model of Granisetron G) SC CR Granisetron 2.5 mg	81
3-4H	PBPK model of Granisetron H) SC CR Granisetron 5 mg	81
3-4I	PBPK model of Granisetron I) SC CR Granisetron 10 mg	81
3-4J	PBPK model of Granisetron J) SC CR Granisetron 20 mg	81
3-4K	PBPK model of Granisetron K) Intramuscular CR Granisetron 20 mg	81
3-4L	PBPK model of Granisetron L) Transdermal patch Granisetron	81
3-5A	Parameter sensitivity analysis for amisulpride A) Amisulpride for C _{max} using logP, F _{up} and BP	82

Figure No.	Description	Page No.
3-5B	Parameter sensitivity analysis for amisulpride B) Amisulpride for AUC using logP, Fup and BP	83
3-5C	Parameter sensitivity analysis for amisulpride C) Amisulpride for Cmax using Weibull parameters for drug release	83
3-5D	Parameter sensitivity analysis for amisulpride D) Amisulpride for AUC using Weibull parameters for drug release	84
3-6A	Parameter sensitivity analysis for Granisetron A) Granisetron for Cmax using logP, Fup, BP and Peff	85
3-6B	Parameter sensitivity analysis for Granisetron B) Granisetron for AUC using logP, Fup, BP and Peff	85
3-6C	Parameter sensitivity analysis for Granisetron C) Granisetron for Cmax using Weibull parameters for drug release	86
3-6D	Parameter sensitivity analysis for Granisetron D) Granisetron for AUC using Weibull parameters for drug release	86
3-7	Fold error for Amisulpride formulations	91
3-8	Fold error for Granisetron Formulations	92
3-9A	Multiple dose simulations for A) Amisulpride oral 5 mg (Q24hr)	93
3-9B	Multiple dose simulations for B) Amisulpride oral 10 mg (Q24hr)	94
3-9C	Multiple dose simulations for C) Granisetron oral 2 mg (Q24hr)	94
3-9D	Multiple dose simulations for D) Granisetron oral 1 mg (Q12hr)	95
4-1	UV Spectrum of Amisulpride	104
4-2	UV Spectrum of Granisetron	104
4-3A	FTIR Spectrum of A) Amisulpride	105
4-3B	FTIR Spectrum of B) Granisetron	105
4-3C	FTIR Spectrum of C) PLGA	106
4-3D	FTIR Spectrum of D) PCL	106
4-3E	FTIR Spectrum of E) PVA	106
4-4A	DSC data of A) Amisulpride	108
4-4B	DSC data of B) Granisetron	108
4-4C	DSC data of C) PLGA	109

Figure No.	Description	Page No.
4-4D	DSC data of D) PCL	109
5-1	Absorption spectrum of Amisulpride in UV	119
5-2	Absorption spectrum of Granisetron in UV	119
5-3	Absorption spectrum of Amisulpride and Granisetron in UV	120
5-4	Calibration curve of Amisulpride in 0.1N HCl at initial in UV	121
5-5	Calibration curve of Amisulpride in 0.1N HCl after 24 hours in UV	121
5-6	Calibration curve of Granisetron in 0.1N HCl at initial in UV	123
5-7	Calibration curve of Granisetron in 0.1N HCl after 24 hours in UV	124
5-8	Placebo Spectrum in UV	125
5-9	Formulation spectrum in UV	125
5-10A	HPLC Chromatogram data A) Amisulpride	126
5-10B	HPLC Chromatogram data B) Granisetron	126
5-10C	HPLC Chromatogram data C) Mixture	126
5-11A	Calibration curve A) at Initial for Amisulpride in HPLC	127
5-11B	Calibration curve B) at Initial for Granisetron in HPLC	128
5-12A	Calibration curve A) at 24h for Amisulpride in HPLC	128
5-12B	Calibration curve B) at 24h for Granisetron in HPLC	129
5-13	Formulation chromatograph in HPLC	130
6-1	Ishikava diagram to assess the impact of different variables on microspheres	135
6-2A	Main effect plot for Particle size (D90)	144
6-2B	Pareto chart for Particle size (D90) in screening design	144
6-2C	Contour plot for Particle size (D90)	145
6-3A	Main effect plot for Entrapment efficiency of Amisulpride	147
6-3B	Pareto chart for Entrapment efficiency of Amisulpride in screening design	147
6-3C	Contour plot for Entrapment efficiency of Amisulpride	148
6-3D	Main effect plot for Entrapment efficiency of Granisetron	148
6-3E	Pareto chart for Entrapment efficiency of Granisetron in screening design	149

Figure No.	Description	Page No.
6-3F	Contour plot for Entrapment efficiency of Granisetron	149
6-4A	Main effect plot for Drug loading of Amisulpride	153
6-4B	Pareto chart for Drug loading of Amisulpride in screening design	154
6-4C	Contour plot for Drug loading of Amisulpride	154
6-4D	Main effect plot for Drug loading of Granisetron	155
6-4E	Pareto chart for Drug loading of Granisetron in screening design	155
6-4F	Contour plot for Drug loading of Granisetron	156
6-5	Response optimization plot	159
6-6A	Pareto chart of Particle size D90 in confirmatory trials	163
6-6B	Surface plot for particle size D90	163
6-7A	Pareto chart for EE of Amisulpride in confirmatory trials	166
6-7B	Surface plot for EE Amisulpride	166
6-7C	Pareto chart for EE of Granisetron in confirmatory trials	167
6-7D	Surface plot for EE Granisetron	167
6-8A	Pareto chart for Drug loading of Amisulpride in confirmatory trials	171
6-8B	Surface plot for Drug loading of Amisulpride	171
6-8C	Pareto chart for Drug loading of Granisetron in confirmatory trials	172
6-8D	Surface plot for Drug loading of Granisetron	172
6-9A	Pareto chart for DR at 4-hour for Amisulpride	176
6-9B	Surface plot for DR 4-hour for Amisulpride	176
6-9C	Pareto chart for DR at 4-hour for Granisetron	177
6-9D	Surface plot for DR 4-hour for Granisetron	177
6-10	Design space for formulation	182
7-1	FTIR spectrum of Optimized formulation	186
7-2	DSC of Optimized formulation	187
7-3	DSC of placebo	187
7-4	Particle size distribution of Optimized formulation	188

Figure No.	Description	Page No.
7-5A	Optical microscopic image A Nascent stage (During process)	189
7-5B	Optical microscopic image B Nascent stage (During process)	189
7-5C	Optical microscopic image C Nascent stage (During process)	189
7-5D	Optical microscopic image D Nascent stage (During process)	189
7-5E	Optical microscopic image E After drying (Finished product)	189
7-5F	Optical microscopic image F After drying (Finished product)	189
7-5G	Optical microscopic image G After drying (Finished product)	189
7-5H	Optical microscopic image H After drying (Finished product)	189
7-6A	Scanning microscopy image of optimized Formulation, A)	190
7-6B	Scanning microscopy image of optimized Formulation, B)	190
7-6C	Scanning microscopy image of optimized Formulation, C)	191
7-7	IVRT data from Accelerated <i>in-vitro</i> release testing method	193
7-8	IVRT data from Real time <i>in-vitro</i> release testing method	195
7-9	<i>In-vitro</i> gel diffusion system setup	196
7-10	IVRT data from Gel diffusion <i>in-vitro</i> release testing method	197
7-11	Stability data Trend at studied stations	201
7-12	Prediction of <i>in-vivo</i> PK for once a weekly formulation of Amisulpride	202
7-13	Prediction of <i>in-vivo</i> PK for once a weekly formulation of Granisetron	203
7-14	Virtual bioequivalence of once a weekly formulation of Amisulpride (30 mg CR) against oral 10 mg multiple dosing	203
7-15	Virtual bioequivalence of once a weekly formulation of Granisetron (10 mg CR) against oral 1 mg multiple dosing	204
7-16A	<i>In-vitro</i> drug release profiles of Amisulpride formulations with different release rates in real time method	205
7-16B	<i>In-vitro</i> drug release profiles of Granisetron formulations with different release rates in real time method	205
7-17	IVIVC predictions for Amisulpride	206
7-18	IVIVC predictions for Granisetron	207